(CercleFinance.com) – MedinCell gained more than 9% in Paris, helped by an analysis by Oddo which maintained its ‘outperformance’ rating on the stock with a price target raised from 11 to 14 euros.
With a return from the FDA expected in the coming weeks (Q2 2023), the approval followed by the commercial launch of Uzedy (mdc-IRM) is the main catalyst for the title in the short term, believes the analyst office.
For Oddo, this consecration will mark both MedinCell’s transition from an R&D biotech to a commercial company, but also will further enhance the credibility of its BEPO platform for obtaining new partnerships.
Finally, in addition to Uzedy’s approval, MedinCell’s newsflow over the next few months should be marked by the clinical progress of its two other active ingredients, mdcCWM (celecoxib) for the management of post-operative pain and mdcTJK (olanzapine) in schizophrenia.
“We expect phase III results respectively at the end of 2023 and Q3/Q4 2024”, concludes the analyst.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
